Clinical Studies for
Patients with Pancreatic Cancer
Category B
These studies are for patients with potentially resectable adenocarcinoma of the pancreas and without a tissue diagnosis of cancer.
| Double-blind, placebo-controlled,
randomized phase III study comparing marimastat to placebo as adjuvant
(postoperative) therapy in patients with resectable pancreatic cancer
(multiinstitutional study) (Protocol ID97-211) Study Chairman: Peter W. T. Pisters, MD Study Sponsor: British Biotech, Inc. This study is now closed to new patients. |